Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

The management of severe chronic pain with a focus on new treatment modalities.

McGuire D, Luther RR, DuBois M.

Drugs Today (Barc). 1998 May;34(5):481-6.

PMID:
15010710
2.

Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.

Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D.

JAMA. 2004 Jan 7;291(1):63-70.

PMID:
14709577
3.

Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group.

Tumlin JA, Dunbar LM, Oparil S, Buckalew V, Ram CV, Mathur V, Ellis D, McGuire D, Fellmann J, Luther RR.

Acad Emerg Med. 2000 Jun;7(6):653-62.

4.

Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.

Atanassoff PG, Hartmannsgruber MW, Thrasher J, Wermeling D, Longton W, Gaeta R, Singh T, Mayo M, McGuire D, Luther RR.

Reg Anesth Pain Med. 2000 May-Jun;25(3):274-8.

PMID:
10834782
5.

Effects of an N-type calcium channel antagonist (SNX 111; Ziconotide) on calcium-45 accumulation following fluid-percussion injury.

Samii A, Badie H, Fu K, Luther RR, Hovda DA.

J Neurotrauma. 1999 Oct;16(10):879-92.

PMID:
10547097
6.

Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects.

Taylor AA, Shepherd AM, Polvino W, Mangoo-Karim R, Ballard K, Sunthornyothin S, Luther RR, Pool JL.

Am J Hypertens. 1999 Sep;12(9 Pt 1):906-14.

PMID:
10509549
7.

The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.

Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D, Epstein M, Luther RR.

Crit Care Med. 1999 Sep;27(9):1832-7.

PMID:
10507606
8.

Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises.

Oparil S, Aronson S, Deeb GM, Epstein M, Levy JH, Luther RR, Prielipp R, Taylor A.

Am J Hypertens. 1999 Jul;12(7):653-64. Review.

PMID:
10411362
9.
10.

Peripheral versus central potencies of N-type voltage-sensitive calcium channel blockers.

Wang YX, Bezprozvannaya S, Bowersox SS, Nadasdi L, Miljanich G, Mezo G, Silva D, Tarczy-Hornoch K, Luther RR.

Naunyn Schmiedebergs Arch Pharmacol. 1998 Feb;357(2):159-68.

PMID:
9521489
11.
12.

Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans.

McGuire D, Bowersox S, Fellmann JD, Luther RR.

J Cardiovasc Pharmacol. 1997 Sep;30(3):400-3.

PMID:
9300326
13.

Pharmacokinetics of SNX-111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys.

Bowersox S, Mandema J, Tarczy-Hornoch K, Miljanich G, Luther RR.

Drug Metab Dispos. 1997 Mar;25(3):379-83.

PMID:
9172958
15.

Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain.

Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, Luther RR.

J Pharmacol Exp Ther. 1996 Dec;279(3):1243-9.

PMID:
8968347
16.

Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.

Gupta SK, Granneman GR, Boger RS, Hollenberg NK, Luther RR.

Drug Metab Dispos. 1992 Nov-Dec;20(6):821-5.

PMID:
1362933
17.

Renin inhibitors in hypertension.

Luther RR, Glassman HN, Boger RS.

Clin Nephrol. 1991 Oct;36(4):181-6. Review.

PMID:
1959244
18.

Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.

Neutel JM, Luther RR, Boger RS, Weber MA.

Am Heart J. 1991 Oct;122(4 Pt 1):1094-100.

PMID:
1656720
19.

Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.

Weber MA, Cheung DG, Laddu AR, Luther RR.

Am Heart J. 1991 Sep;122(3 Pt 2):905-10.

PMID:
1678921
20.

Effects of renin inhibition in systemic hypertension.

Anderson PW, Do YS, Schambelan M, Horton R, Boger RS, Luther RR, Hsueh WA.

Am J Cardiol. 1990 Dec 1;66(19):1342-7.

PMID:
2244565
21.

Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension.

Boger RS, Glassman HN, Cavanaugh JH, Schmitz PJ, Lamm J, Moyse D, Cohen A, Kleinert HD, Luther RR.

Hypertension. 1990 Jun;15(6 Pt 2):835-40.

PMID:
2190927
22.

Effects of terazosin on serum lipid levels in hypertensive blacks.

Luther RR, Klepper MJ, Maurath CJ, Glassman HN, Achari R, Laddu AR.

J Hum Hypertens. 1990 Apr;4(2):154-6.

PMID:
1971028
23.

Efficacy of terazosin in the treatment of essential hypertension in blacks.

Luther RR, Klepper MJ, Maurath CJ, Glassman HN, Achari R, Laddu AR.

J Hum Hypertens. 1990 Apr;4(2):151-3.

PMID:
1971027
24.

Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.

Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR.

J Cardiovasc Pharmacol. 1990;16 Suppl 4:S76-81. Review.

PMID:
1705633
25.

New perspectives on selective alpha 1 blockade.

Luther RR.

Am J Hypertens. 1989 Sep;2(9):729-35. Review.

PMID:
2572243
26.

Terazosin: a new antihypertensive agent with favorable effects on lipids.

Luther RR.

Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):313-9. Review.

PMID:
2570758
27.

Toxicity of uricosuric diuretics in rat hepatocyte culture.

Tolman KG, Gray PD, el Masry S, Luther RR, Janicki RS.

Biochem Pharmacol. 1989 Apr 1;38(7):1181-4.

PMID:
2706015
28.

The effects of terazosin and methyclothiazide on blood pressure and serum lipids.

Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC.

Am Heart J. 1989 Apr;117(4):842-7.

PMID:
2564723
29.

Renin inhibitors: specific modulators of the renin-angiotensin system.

Luther RR, Stein HH, Glassman HN, Kleinert HD.

Arzneimittelforschung. 1989 Jan;39(1):1-5. Review.

PMID:
2655608
30.

Pharmacologic effects of A-56234, a new high-ceiling diuretic.

Luther RR, Ringham GL, Thomas EW, Patterson KJ, Tolman KG.

J Clin Pharmacol. 1988 Sep;28(9):795-803.

PMID:
3230146
31.

A comparison of carteolol and nadolol in the treatment of stable angina pectoris.

Luther RR, Glassman HN, Jordan DC.

J Clin Pharmacol. 1988 Jul;28(7):634-9.

PMID:
3063728
32.

Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.

Luther RR, Glassman HN, Estep CB, Schmitz PJ, Horton JK, Jordan DC.

Am J Hypertens. 1988 Jul;1(3 Pt 3):237S-240S.

PMID:
2901267
33.

Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity.

Kleinert HD, Martin D, Chekal MA, Kadam J, Luly JR, Plattner JJ, Perun TJ, Luther RR.

Hypertension. 1988 Jun;11(6 Pt 2):613-9.

PMID:
3292414
34.

Effect of age on the pharmacokinetics of orally and intravenously administered terazosin.

Sennello LT, Sonders RC, Glassman HN, Jordan DC, Luther RR, Tolman KG.

Clin Ther. 1988;10(5):600-7.

PMID:
2908805
35.

Pharmacologic effects of A-49816, a new high-ceiling diuretic.

Luther RR, Ringham GL, Steinberg FJ, Patterson KJ, Jordan DC, Rollins DE, Tolman KG.

J Clin Pharmacol. 1987 Oct;27(10):794-801.

PMID:
3323256
36.

Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.

Luther RR, Glassman HN, Sperzel WD, Steinberg FJ, Horton JK, Jordan DC.

J Hypertens Suppl. 1986 Dec;4(5):S494-7. Review.

PMID:
2883273
37.

Overall safety of terazosin as an antihypertensive agent.

Sperzel WD, Glassman HN, Jordan DC, Luther RR.

Am J Med. 1986 May 23;80(5B):77-81.

PMID:
2872812
38.

Efficacy of terazosin as an antihypertensive agent.

Luther RR, Glassman HN, Jordan DC, Sperzel WD.

Am J Med. 1986 May 23;80(5B):73-6.

PMID:
2872811
39.

Clinical trials with terazosin. General methods.

Sperzel WD, Luther RR, Glassman HN.

Am J Med. 1986 May 23;80(5B):25-8.

PMID:
2872803
40.

Carteolol treatment of essential hypertension: a long-term study of safety and efficacy.

Luther RR, Maurath CJ, Klepper MJ, Peckinpaugh RO, Ringham GL.

J Int Med Res. 1986;14(4):175-84.

PMID:
3758467
41.

Long-term treatment of angina pectoris with carteolol: a new beta-adrenergic receptor blocking agent.

Luther RR, Glassman HN, Jordan DC, Klepper MJ.

J Int Med Res. 1986;14(4):167-74.

PMID:
3093295
42.

Anaphylaxis: etiology and guidelines for management.

Morrow DH, Luther RR.

Anesth Analg. 1976 Jul-Aug;55(4):493-9.

PMID:
60069
43.

Acute mitral insufficiency secondary to ruptured chrodae tendineae.

Luther RR, Meyers SN.

Arch Intern Med. 1974 Sep;134(3):568-8. Review. No abstract available.

PMID:
4604063

Supplemental Content

Loading ...
Support Center